Published: December 31, 2014

InSphero Granted Hanging Drop Patents in China and Japan

InSphero Granted Hanging Drop Patents in China and Japan

Schlieren, Switzerland, February 27, 2014 – InSphero adds GravityPLUS™ patents in major Asian markets to existing European & Singapore patents, awaits decision on pending US patent. 

The Patent Office of the People’s Republic of China and the Japan Patent Office granted InSphero full protection of its GravityPLUS™ hanging-drop technology in January 2014. A decision from the US Patent Office is expected to follow within the coming months.

InSphero’s core patent WO2010031194 describes multiwell plates, which allow the generation of hanging drops for 3D cell culture using convenient top loading of the cell suspension. InSphero has commercialized a number of SBS-compatible 3D cell culture plates for spheroid generation, which are based on this patent.

Commenting on this favorable decision for InSphero, CEO Dr. Jan Lichtenberg noted, “We are excited to add patents in these two important marketplaces to our existing patent portfolio for the GravityPLUS™ technology. These patents further protect the market from imitations of our hanging drop plates, and we hope to secure similar protection in the US market in the near future. We, like our customers, understand the importance of intellectual property in our industry as it protects the efforts and investments made in the creation of new technology. ”

To find out more about InSphero, browse our website.

Other News

News

InSphero Appoints Dr. Olivier Frey as Chief Operating Officer and Chief Technology Officer

InSphero has appointed Dr. Olivier Frey as Chief Operating Officer and Chief Technology Officer, expanding his leadership role as the company continues to grow and scale. With nearly a decade at InSphero and deep expertise across microfluidics, BioMEMS, 3D in vitro models, and organ-on-chip technologies, Olivier will bring technology and operations into closer alignment. In his new role, he will help advance operational efficiency, digitalization, automation, and technology development across the organization.

Read More »
News

InSphero Launches 3D InSight™ DIGIT Platform for Early Gastrointestinal Toxicity Assessment 

InSphero has launched the 3D InSight™ Drug-Induced Gastrointestinal Toxicity (DIGIT) platform, a standardized, high-throughput solution designed to identify gastrointestinal safety liabilities earlier in drug discovery. Combining patient-derived human intestinal organoids, scalable Gri3D® technology, and automated phenotypic imaging, the platform delivers quantitative, decision-ready insights while enabling more consistent and streamlined GI safety assessment.

Read More »

Your Success is Our Mission - Get in Touch

Fill in form below to contact our 3D in vitro experts

Sign up for our Newsletter

Get the latest news on 3D in vitro research

View resource

Fill in the form below to view this resource